دورية أكاديمية

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.

التفاصيل البيبلوغرافية
العنوان: Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
المؤلفون: Mishra, Neha, Aden, Konrad, Blase, Johanna I, Baran, Nathan, Bordoni, Dora, Tran, Florian, Conrad, Claudio, Avalos, Diana, Jaeckel, Charlot, Scherer, Michael, Sørensen, Signe B, Overgaard, Silja H, Schulte, Berenice, Nikolaus, Susanna, Rey, Guillaume, Gasparoni, Gilles, Lyons, Paul A, Schultze, Joachim L, Walter, Jörn, Andersen, Vibeke, SYSCID Consortium, Dermitzakis, Emmanouil T, Schreiber, Stefan, Rosenstiel, Philip
المساهمون: Georges, Michel
المصدر: Genome Medicine, 14 (1), 110 (2022-09-24)
بيانات النشر: BioMed Central Ltd, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Biologics, Biomarker, Intestinal inflammation, Personalized medicine, Therapy response, Biomarkers, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha, RNA, Interferons, Infliximab, Humans, Infliximab/therapeutic use, Interferons/therapeutic use, Prospective Studies, Inflammatory Bowel Diseases/drug therapy, Inflammatory Bowel Diseases/genetics, Inflammatory Bowel Diseases, Molecular Medicine, Molecular Biology, Genetics, Genetics (clinical), Life sciences, Genetics & genetic processes, Sciences du vivant, Génétique & processus génétiques
الوصف: [en] BACKGROUND AND AIMS: Treatment with tumor necrosis factor α (TNFα) antagonists in IBD patients suffers from primary non-response rates of up to 40%. Biomarkers for early prediction of therapy success are missing. We investigated the dynamics of gene expression and DNA methylation in blood samples of IBD patients treated with the TNF antagonist infliximab and analyzed the predictive potential regarding therapy outcome.METHODS: We performed a longitudinal, blood-based multi-omics study in two prospective IBD patient cohorts receiving first-time infliximab therapy (discovery: 14 patients, replication: 23 patients). Samples were collected at up to 7 time points (from baseline to 14 weeks after therapy induction). RNA-sequencing and genome-wide DNA methylation data were analyzed and correlated with clinical remission at week 14 as a primary endpoint.RESULTS: We found no consistent ex ante predictive signature across the two cohorts. Longitudinally upregulated transcripts in the non-remitter group comprised TH2- and eosinophil-related genes including ALOX15, FCER1A, and OLIG2. Network construction identified transcript modules that were coherently expressed at baseline and in non-remitting patients but were disrupted at early time points in remitting patients. These modules reflected processes such as interferon signaling, erythropoiesis, and platelet aggregation. DNA methylation analysis identified remission-specific temporal changes, which partially overlapped with transcriptomic signals. Machine learning approaches identified features from differentially expressed genes cis-linked to DNA methylation changes at week 2 as a robust predictor of therapy outcome at week 14, which was validated in a publicly available dataset of 20 infliximab-treated CD patients.CONCLUSIONS: Integrative multi-omics analysis reveals early shifts of gene expression and DNA methylation as predictors for efficient response to anti-TNF treatment. Lack of such signatures might be used to identify patients with IBD unlikely to benefit from TNF antagonists at an early time point.
نوع الوثيقة: journal article
http://purl.org/coar/resource_type/c_6501
article
peer reviewed
اللغة: English
Relation: info:eu-repo/grantAgreement/EC/H2020/733100; https://link.springer.com/content/pdf/10.1186/s13073-022-01112-z.pdf; urn:issn:1756-994X
DOI: 10.1186/s13073-022-01112-z
URL الوصول: https://orbi.uliege.be/handle/2268/302286
حقوق: open access
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
رقم الأكسشن: edsorb.302286
قاعدة البيانات: ORBi
الوصف
DOI:10.1186/s13073-022-01112-z